Abstract
DFT‐calculations allow prediction of the reactivity of uncommon N‐heterocyclic scaffolds of pyrazolo[1,5‐a]pyrimidines and imidazo[1,2‐b]pyridazines and considerably facilitate their functionalization. The derivatization of these N‐heterocycles was realized using Grignard reagents for nucleophilic additions to 5‐chloropyrazolo[1,5‐a]pyrimidines and TMP2Zn ⋅ 2 MgCl2 ⋅ 2 LiCl allowed regioselective zincations. In the case of 6‐chloroimidazo[1,2‐b]pyridazine, bases such as TMP2Zn ⋅ MgCl2 ⋅ 2 LiCl, in the presence or absence of BF3 ⋅ OEt2, led to regioselective metalations at positions 3 or 8. Subsequent functionalizations were achieved with TMPMgCl ⋅ LiCl, producing various polysubstituted derivatives (up to penta‐substitution). X‐ray analysis confirmed the regioselectivity for key functional heterocycles.
Keywords: DFT calculation, imidazopyridazines, magnesium, N-heterocycle, pyrazolopyrimidines
N‐heterocycles, pyrazolopyrimidines and imidazopyridazines were reliably functionalized with the support of DFT ‐ calculations using Grignard reagents as nucleophilic partners and TMPZn‐mediated zincations for 5‐chloropyrazolo[1,5‐a]pyrimidine. Successive regioselective magnesiations with TMPMgCl⋅LiCl or TMP2Zn⋅MgCl2 ⋅ 2 LiCl in the presence or absence of BF3 ⋅ OEt2 for the 6‐chloroimidazo[1,2‐b]pyridazine scaffold provided a range of highly functionalized new N‐heterocycles of pharmaceutical interest.
Introduction
N‐Heterocycles are key scaffolds for various applications, especially in pharmaceutical and agrochemical research. [1] Monocyclic N‐heterocycles, including pyridines, pyrimidines, pyridazines, pyrroles, imidazoles and pyrazoles, as well as benzo‐derivatives of these skeletons such as indoles and quinolines, have found numerous applications. [2] The synthesis of new N‐heterocyclic cores are being actively investigated; the interest being, triggered by their potential new physicochemical and medicinal properties and favorable pharmacokinetics. [3] Two promising isomeric N‐heterocycles, containing three nitrogen atoms embedded in a [4.3.0]‐ring system, are pyrazolo[1,5‐a]pyrimidines (1 a) and imidazo[1,2‐b]pyridazines (2 a). These systems have been chosen based on the potential high impact of the pyrazolo[1,5‐a]pyrimidine scaffold for pharmaceutical applications. [4] Thus, pyrazolo[1,5‐a]pyrimidines such as zaleplon (3), a sedative and hypnotic agent, [5] the pain regulator larotrectinib 4, [6] and the kinase inhibitor 5, [7] are representative biomolecules of this important class of bicyclic N‐heterocycles. [8] The antiplasmodial imidazopyridazine 6 [9] is also representative for this second class of bicyclic N‐heterocycles (Figure 1).
Figure 1.
General structures of pyrazolo[1,5‐a]pyrimidines 1 a and imidazo[1,2‐b]pyridazines 2 a as well as chloro‐derivatives 1 b and 2 b including calculated pKa‐values (DMSO), as well as drugs or drug candidates of these N‐heterocycle classes.
The predictive decoration of these new heterocyclic scaffolds is an important synthetic challenge. The principle of predictive functionalization has been successfully applied to various N‐heterocycles using theoretical computational methods such as molecular mechanics (MM) and density‐functional theory (DFT). [10] Such approaches may allow a differentiation of all possible ring positions and an assessment of the electrophilicity of each carbon as well as the acidity of each ring proton. To facilitate such reactivity differences, we choose to start with the mono‐chloro‐substituted compounds 1 b and 2 b, assuming that the chlorine substituent can be readily replaced with various functional groups at a later stage. [11]
Herein, we report a range of selective functionalizations of the isomeric N‐heterocycles 1 b and 2 b with the help of theoretical investigations. Remarkably, this study led to a new nucleophilic addition procedure on heterocycles derived from pyrazolo[1,5‐a]pyrimidine (1 a). This nucleophilic addition considerably expands the functionalization opportunities of scaffold 1 a and complements metalations of 1 a with TMP‐bases (TMP=2,2,6,6‐tetramethylpiperidyl). In the case of N‐heterocycles of type 2 a, calculations showed that successive metalations should allow their full regioselective decoration. These successful functionalizations of 1 b and 2 b are described below.
Results and Discussion
We have initiated our investigations by calculating the pK a‐values of all ring protons in compounds 1 a, 1 b, 2 a and 2 b as well as the BF3‐complex 2 c using previously developed computational protocol [10e] (Figure 1). These pK a‐values clearly indicated that position 7 of the pyrazolo[1,5‐a]pyrimidines 1 b is the most acidic and should be selectively metalated. On the other hand, in the case of the chlorinated imidazo[1,2‐b]pyridazine 2 b the predicted pK a‐values of H3 and H8 were identical. Thus, thermodynamic considerations will not allow a differentiation of these positions. However, kinetic considerations involving the complex‐induced proximity effect (CIPE) introduced by Snieckus and Beak [12] clearly favor position 8 for a first metalation due to the preferred coordination of the metallic base to the most basic N(1)‐atom. We have also examined the coordination of a strong Lewis acid such as BF3 ⋅ OEt2 to the nitrogen atoms of 2 b in order to induce a pK a change and have explored the impact of this change on the metalation regioselectivity. Initial calculations indicated that the thermodynamically preferred site for Lewis acid coordination is N1 (see structure 2 c, Figure 1).
This coordination lowered the pK a‐values of all protons in the Lewis acid adduct. However, the position 3 was clearly most acidified, indicating that a regioselectivity switch of the metalation might be induced through a coordination with BF3 ⋅ OEt2 before the addition of the TMP‐base. [13] Finally, we have calculated the electrophilicity of the various ring positions by using methyl anion affinities (MAA) [14] as indicated in Figure 2. Thus, the MAA of various positions for 1 b and 2 b have been determined, showing that position 7 of 1 b was highly activated towards a nucleophilic attack (MAA(C7)=−102.0 kJ/mol). On the other hand, for the imidazo[1,2‐b]pyridazine 2 b the corresponding position C8 was significantly less electrophilic (MAA(C8)=−80.3 kJ/mol). In summary, the pyrazolo[1,5‐a]pyrimidine 1 b is expected to coordinate metallic bases such as TMPMetX (Met=Zn, Mg; X=Hal), or organometallic reagents RMetX preferentially at N (1) allowing both metalations or nucleophilic addition via primary complexes A or B (Scheme 1).
Figure 2.
Methyl anion affinity values (MAA, in kJ/mol) calculated at SMD‐(DMSO)/B3LYP/6‐311++G(3df,2pd) //B3LYP/6‐31G(d,p) level of theory. [a] Addition of methyl anion leads to Cl elimination.
Scheme 1.
Predicted reactivity of the 5,6‐fused bicyclic heterocycle 5‐chloropyrazolo[1,5‐a]pyrimidine 1 b. Met=Zn, Mg.
After metalation or nucleophilic addition, the organometallic intermediate 7 or 8 should be obtained. Reaction with an electrophile (E−X) or oxidative workup would yield functionalized pyrazolo[1,5‐a]pyrimidines of type 9 or 10. Concerning 6‐chloroimidazo[1,2‐b]pyridazine (2 b), a complexation of either TMPMetX or BF3 ⋅ OEt2 at the most basic N(1)‐nitrogen atom should provide the complexes C and D. This complex C will readily lead to the metalation of position 8 affording the organometallic species 11 which after reaction with an electrophile E−X will afford 8‐functionalized 6‐chloroimidazo[1,2‐b]pyridazine of type 12. Alternatively, the complexation with BF3 ⋅ OEt2 leading to the adduct D, will complex TMPMetX at the next basic nitrogen atom N(5), providing the complex E. By proximity, complex E will lead to a metalation at position 3 furnishing the organometallic species 13, which after subsequent quenching with an electrophile E−X will give 3‐functionalized imidazopyridazines of type 14 (Scheme 2).
Scheme 2.
Predicted reactivity of the 5,6‐fused bicyclic heterocycle 6‐chloroimidazo[1,2‐b]pyridazine 2 b. Met=Zn, Mg.
According to these predictions, we first investigated the metalation of the pyrazolo[1,5‐a]pyrimidine 1 b and have found that TMP2Zn ⋅ 2 MgCl2 ⋅ 2 LiCl [15] (15) in THF led to a selective zincation at the predicted 7‐position at −40 °C within 10 min, affording the diheteroarylzinc derivative 16. The use of TMPMgCl ⋅ LiCl [16] (17) and other related bases were much less satisfactory. [17] The quenching of the organozinc intermediate 16 with various electrophiles provided disubstituted pyrazolo[1,5‐a]pyrimidines 18 a‐18 f in 48–81 % isolated yield (Scheme 3). Thus, iodolysis of 16 gave the corresponding iodo‐derivative 18 a in 81 % yield. Treatment of 16 with CuCN ⋅ 2 LiCl [18] (50 mol%) followed by the addition of benzoyl chloride derivatives (25 °C, 2 h) furnished the ketones 18 b and 18 c in 48–54 % yield. Negishi cross‐couplings [19] of the diheteroarylzinc derivative 16 with various aryl iodides in the presence of catalytic amounts of Pd(dba)2 (5 mol%; dba=dibenzylideneacetone) and tfp [20] (10 mol%; tfp=tri(2‐furyl)phosphine, 40 °C, 2 h) gave the arylated N‐heterocycles 18 d–18 f in 65–79 % isolated yield.
Scheme 3.
The selective metalation of the pyrazolo[1,5‐a]pyrimidine 1 b at position 7 using TMP2Zn ⋅ 2 MgCl2 ⋅ 2 LiCl (15). Reagents and conditions: (i) TMP2Zn ⋅ 2 MgCl2 ⋅ 2 LiCl (15, 0.55 equiv.), THF, −40 °C, 10 min; (ii) E−X, [b] THF, 25 °C, 2 h, the acylation was mediated by CuCN ⋅ 2 LiCl (50 mol%). [c] THF, 40 °C, 2 h, the cross‐coupling was catalyzed by Pd(dba)2 (5 mol%) and tfp (10 mol%). [a] Isolated yields of analytically pure product.
Although the nucleophilic addition to electron‐deficient heterocycles was reported previously, [21] only a few classes of N‐heterocycles besides pyridines led to practical applications. [22] In addition, most reported nucleophilic addition reactions to N‐heterocycles required either very harsh conditions or a preactivation via ionic intermediates such as pyridinium ions. [23] Based on the previously mentioned theoretical calculations (Figure 2), we treated pyrazolo[1,5‐a]pyrimidine (1 b) with various organometallics, of which organomagnesium halides complexed with lithium chloride of type 19 [24] gave the best results (Scheme 4). Thus, the addition of 3‐methoxyphenylmagnesium bromide‐lithium chloride (19 a, 1.2 equiv. in THF) to chloropyrazolopyrimidine (1 b) at −20 °C was complete within 10 min. The intermediate magnesium species was then trapped with PhSO2SMe [25] (1.2 equiv., 25 °C, 1 h) leading to a single trans‐diastereomer of type 20. [26] These partially saturated heterocycles proved not to be bench‐stable and decomposed slowly over time. Therefore, these compounds were directly oxidized with DDQ (DDQ=2,3‐dichloro‐5,6‐dicyano‐1,4‐benzoquinone, 1.2 equiv., 40 °C, 5–7 h) in THF, furnishing the tri‐substituted pyrazolo[1,5‐a]pyrimidine 21 a in 65 % overall yield. An addition of 19 a to 1 b followed by an aqueous work‐up and DDQ‐oxidation, gave the di‐substituted N‐heterocycle 21 b in 48 % yield. This reaction sequence was also extended to other electrophiles. Thus, the addition of ethyl cyanoformate (2.0 equiv., 25 °C, 3 h) gave the polyfunctional N‐heterocycle 21 c in 60 % yield. Also, copper‐mediated acylation with pivaloyl chloride furnished the ketone 21 d in 47 % yield. Other arylmagnesium reagents such as 4‐chlorophenyl‐magnesium bromide (19 b) or 3,5‐dimethylphenylmagnesium bromide (19 c) gave the expected pyrazolopyrimidine 21 e and 21 f in 54–67 % yield after PhSO2SMe quench and rearomatization with DDQ. The nucleophilic addition of alkylmagnesium reagents was also possible, as demonstrated by use of iPrMgCl ⋅ LiCl. Various trapping reactions with PhSO2SMe, PhCOCl and NCCO2Et followed by a DDQ oxidation gave the expected products 21 g‐21 i in 44–60 % overall yield (Scheme 4).
Scheme 4.
5,6,7‐Trisubstituted pyrazolo[1,5‐a]pyrimidines 21 a–21 i prepared by the nucleophilic addition of organomagnesium halides (19) to the pyrazolo‐[1,5‐a]pyrimidine 1 b, followed by electrophilic quenching reactions and DDQ oxidation. Reagents and conditions: (i) RMgX ⋅ LiCl (19, 1.2 equiv.), THF, −20 °C, 10 min; (ii) E−X; aqueous work‐up; (iii) DDQ (1.2 equiv.), THF, 40 °C 5–7 h. [a] Isolated yield of analytically pure compounds. [b] The acylation was mediated by CuCN ⋅ 2 LiCl (50 mol%).
As mentioned above, the partially reduced adducts of type 20 were moderately stable. However, we were able to isolate the 7,6‐disubstituted product 20 a, in 78 % yield (Scheme 5).
Scheme 5.
Nucleophilic addition of Grignard reagents 19 to the pyrazolo[1,5‐a]pyrimidine (1 b) followed by reductive quenching leading to annulated pyrazines 20 a, 22 a‐22 b. Reagents and conditions: (i) RMgX ⋅ LiCl (19, 1.2 equiv.), THF, −20 °C, 10 min; (ii) E−X; (iii) aqueous work‐up; (iv) Na(CN)BH3 (2 equiv.), MeOH, 25 °C, 1 M HCl, 2 h. [a] Isolated yield of analytically pure compounds.
This compound could be stored at 0 °C for 2–3 d. Considerably better stabilities were observed for the fully reduced pyrimidine ring products obtained by treating compounds of type 20 with Na(CN)BH3 (2.0 equiv, 1 M HCl, H2O:MeOH, 25 °C, 2 h) providing fused N‐heterocycle 22 a and diastereomerically pure trans‐22 b in 41–56 % isolated yield. Interestingly, the arylation of 1 b with p‐anisylzinc chloride [27] (23, 1.5 equiv.) in the presence of 2.5 % Pd(OAc)2 and 5 % SPhos [28] (50 °C, 1.5 h) gave the fused heterocycle 24 in 70 % yield (Scheme 6). This N‐heterocycle 24 underwent the same sequence (nucleophilic addition, electrophilic quench and reduction) as outlined in Scheme 6, providing the bicyclic pyrazine 25 as a single diastereomer. The relative configuration was established using X‐ray analysis [17] by converting 25 into the corresponding benzamide 26 (PhCOCl, 1.1 equiv.) in 80 % yield.
Scheme 6.
Preparation of the bicyclic pyrazine 24 and derivatization to the corresponding benzoate for X‐ray characterization and post‐functionalization by iodination and Negishi cross‐coupling affording the N‐heterocycle 28. Reagents and conditions: (i) 23, Pd(OAc)2 (2.5 mol%), SPhos (5 mol%), THF, 50 °C, 1.5 h; (ii) iPrMgBr ⋅ LiCl (1.2 equiv.), 0 °C, 20 min; (iii) NCCO2Et (2 equiv.) 25 °C, 2 h; (iv) NaBH3(CN), 25 °C, 2 h; (v) PhCOCl, Et3N, CH2Cl2, 25 °C, 3 h; (vi) NIS (1.0 equiv.), MeCN, 25 °C,1 h; (vii) 23, Pd(OAc)2 (2.5 mol%), SPhos (5 mol%), THF, 50 °C, 1.5 h. [a] Isolated yield of analytically pure compounds.
Furthermore, the post‐functionalization of position 3 of the pyrazine ring of 26 was realized by iodination using NIS [29] (1.0 equiv.) in acetonitrile (25 °C, 1 h), affording the iodo N‐heterocycle 27 in 63 % yield. This iodide was readily arylated by a Negishi cross‐coupling [19] with p‐anisylzinc chloride 23 providing the 3‐arylated heterocycle 28 in 51 % yield (Scheme 6).
Furthermore, we have derivatized tri‐substituted heterocycles 21 c and 21 f in order to prepare highly functionalized derivatives. Thus, treatment of 21 c with pyrrolidine at 25 °C for 2 h provided by an addition‐elimination reaction [30] the aminated product 29 in 92 % yield. Iodination of 29 as described above with NIS gave the 3‐iodinated pyrazine derivative 30 which after Negishi cross‐coupling [19] provided the tetra‐substituted pyrazolopyrimidine 31 in 58 % yield. On another hand, formylation of 29 by a Vilsmeier–Haack reaction [29] using POCl3 in DMF gave the 4‐substituted heterocycle 32 in 74 % yield. The structure of 32 was confirmed by X‐ray analysis. [17] Conversion of 32 to the oxadiazole derivative 33 was achieved by a two‐step sequence in an overall yield of 60 % using benzohydrazide followed by oxidative cyclization. [31] Also, the bromination of 21 f with NBS [32] gave the bromo‐derivative 34 in 96 % yield. Br/Mg‐exchange of 34 with iPrMgCl ⋅ LiCl [33] gave an intermediate magnesium reagent, which was cyanated with TsCN [34] affording the nitrile 35 in 59 % yield (Scheme 7).
Scheme 7.
Post‐functionalization of the pyrazine ring of heterocycles 21 c and 21 f leading to tetra‐substituted pyrazolo[1,5‐a]pyrimidines 31, 33 and 35. Reagents and conditions: (i) Pyrrolidine (1.5 equiv.), THF, 25 °C, 2 h; (ii) NIS, MeCN, 25 °C, 1 h; (iii) 23, Pd(OAc)2 (2.5 mol%), SPhos (5 mol%), THF, 50 °C, 1.5 h; (iv) POCl3, DMF, 25 °C, 12 h; (v) PhCONHNH2, MeOH, 25 °C, 1 h; (vi) K2CO3, I2, dioxane, 80 °C, 3 h; (vii) NBS, MeCN, 25 °C, 1 h; (viii) iPrMgCl ⋅ LiCl, THF, 0 °C, 30 min; (ix) TsCN, 25 °C, 3 h. [a] Isolated yield of analytically pure compounds.
The carbon‐chloride bond of 21 c, 21 d and 21 f was further used to increase the complexity of these heterocycles by straightforward derivatization. Thus, Sonogashira cross‐coupling of 21 c with propargylic alcohol (36) using a dual copper‐palladium catalysis [35] provided the alkynylated product 37 in 59 % yield (Scheme 8).
Scheme 8.
Functionalization of the C−Cl bond of 21 c, 21 d and 21 f providing the polyfunctionalized heterocycles 37, 38 and 39. [a] Isolated yield of analytically pure compounds.
Treatment of 21 d with hydrazine hydrate [36] provided the annulated heterocycle 38 in 62 % yield. Finally, Negishi cross‐coupling [19] of 21 f with PhZnCl ⋅ LiCl furnished the phenylated product 39 in 66 % yield. We turned then our attention to the functionalization of 6‐chloroimidazo[1,2‐b]pyridazine (2 b) according to the prediction depicted in Scheme 2. Thus, we have treated 6‐chloroi‐midazo[1,2‐b]pyridazine (2 b) with TMPMgCl ⋅ LiCl (17) [16] in THF which led to a selective magnesiation at the predicted 8‐position at −60 °C within 30 min, affording magnesiated species of type 40. Thus, iodolysis of 40 afforded the corresponding iodo‐derivative 41 a in 73 % yield (Scheme 9). Treatment of 40 with electrophiles such as PhSO2SMe, PhSO2SPh [25] gave sulfides 41 b, and 41 c in 63–76 % yield whereas, treatment with commercially available TsCN gave cyano‐compound 41 d in 47 % yield. Unfortunately, direct Kumada cross‐coupling [37] of type 40 with aryl iodides gave an unsatisfactory result. We found that, iodide 41 a was readily arylated with different arylzinc derivatives (p‐anisylzinc chloride 23, or p‐carbethoxyphenylzinc chloride lithium chloride 42) via Negishi cross‐coupling [19] in the presence of catalytic amounts of Pd(dba)2 (5 mol%) and tfp [20] (10 mol%, 25 °C, 0.5 h) giving the arylated N‐heterocycles 43 a‐43 b in 83–88 % isolated yield.
Scheme 9.
Selective metalation of predicted 8‐position of 6‐chloroimidazo[1,2‐b]pyridazine (2 b) using TMPMgCl ⋅ LiCl (17) followed by electrophilic quenching. Reagents and conditions: (i) 17 (1.1 equiv.), THF, −60 °C, 30 min; (ii) E−X, THF, 25 °C, 0.1‐2 h; (iii) 23 or 42 (1.5 equiv.), Pd(dba)2 (5 mol%), tfp (10 mol%), THF, 25 °C, 30 min. [a] Isolated yield of analytically pure compounds.
As described above in Scheme 2 a complexation of 2 b with BF3 ⋅ OEt2 [13a] allowed a regioselectivity switch with TMP2Zn ⋅ MgCl2 ⋅ 2LiCl (44) in THF at ‐20 °C within 20 min, affording zincated N‐heterocycle of type 45 (Scheme 10). The quenching of 45 with various electrophiles provided the 3,6‐disubstituted imidazo[1,2‐b]pyridazines 46 a‐46 e in 32–83 %. Thus, iodolysis of 45 provided the corresponding iodo‐derivative 46 a in 83 % yield. Treatment of 45 with CuCN ⋅ 2LiCl (20 mol%) [18] followed by addition of acyl chlorides, allyl bromide (25 °C, 2 h) furnished the ketones 46 b, 46 c and allylated N‐heterocycle 46 d. Negishi cross‐couplings [19] of the diheteroarylzinc derivative 45 with p‐iodoanisole in the presence of catalytic amounts of Pd(PPh3)4 (5 mol%, 40 °C, 2 h) gave the arylated N‐heterocycle 46 e in 67 % isolated yield. The structure of 46 c was confirmed by X‐ray analysis. [17] A second metalation using TMPMgCl ⋅ LiCl (17) was also possible (Scheme 11). Treatment of 6‐chloro‐8‐phenylthio‐N‐heterocycle 41 c (from Scheme 9) with 17 (1.2 equiv., THF, −60 °C, 0.5 h) provided a full conversion to 3‐magnesiated N‐heterocycle 47. This organometallic intermediate was successfully quenched with typical electrophiles providing 3,6‐trisubstituted imidazo[1,2‐b]pyridazines 48 a‐48 e.
Scheme 10.
Zincation in the presence of BF3 ⋅ OEt2 leading to 3‐substituted 6‐chloroimidazo[1,2‐b]pyridazine. Reagents and conditions: (i) BF3⋅OEt2 (1.0 equiv.), 44, (0.6 equiv.); (ii) E−X, THF, 25 °C, 0.1‐2 h. [a] Isolated yield of analytically pure compounds. [b] The acylation was mediated by CuCN ⋅ 2 LiCl (20 mol%). [c] The cross‐coupling was catalyzed by Pd(PPh3)4 (5 mol%).
Scheme 11.
Selective metalation of N‐heterocycle 41 c using TMPMgCl ⋅ LiCl followed by electrophilic quenching affording the N‐heterocycles 48 a‐48 e. Reagents and conditions: (i) 17 (1.2 equiv.), THF, −60 °C, 30 min; (ii) E−X, THF, 25 °C, 0.1‐3 h. [a] Isolated yield of analytically pure compounds. [b] The acylation was mediated by Pd(PPh3)4 (5 mol%). [c] The acylation was mediated by CuCN ⋅ 2 LiCl (20 mol%).
Thus, iodolysis of 47 provided the corresponding iodo‐derivative 48 a in 69 % yield. Treatment of 47 with pivaloyl chloride, allyl bromide in the presence of CuCN ⋅ 2LiCl (20 mol%) or with benzoyl chloride (25 °C, 2 h) in the presence of Pd(PPh3)4 (5 mol%) [38] furnished the ketones 48 b, 48 c in 75–93 % yield and allyl compound 48 d in 70 % yield. Whereas, quenching the intermediate 47 with TsCN (1.5 equiv., 25 °C, 3 h) gave cyano‐derivative 48 e in 77 % yield.
A third functionalization of the imidazo[1,2‐b]pyridazines skeleton was demonstrated on the ketone 48 b (Scheme 12). Therefore, treating 48 b with TMPMgCl ⋅ LiCl (17) in THF at −40 °C within 20 min afforded selectively 2‐magnesiated species of type 49. The quenching of organomagnesium intermediates (49) with various electrophiles provided tetra‐substituted imidazo[1,2‐b]pyridazines 50 a‐50 d. Thus, iodolysis of 49 furnished the corresponding iodo‐derivative 50 a in 83 % yield. Treatment of 49 with TsCN (1.5 equiv., 25 °C, 2 h) gave cyano‐derivative 50 b in 75 % yield. Magnesiated species of type 49 underwent transmetalation [39] with a 1 M THF solution of ZnCl2 (1 equiv.) for 15 min giving a diheteroarylzinc species. The resulting zinc reagents were subjected to cross‐coupling with various aryl iodides in the presence of catalytic amounts of Pd(OAc)2 (5 mol%) and XantPhos [40] (10 mol%, 40 °C, 4 h) to give the arylated N‐heterocycles 50 c‐50 d in 43–70 % isolated yield.
Scheme 12.
Metalation of the tri‐substituted imidazopyridazines 48 c, followed by various quenching reactions. Oxidation of sulfide 50 b to sulfoxide 51 followed by nucleophilic substitution of the C‐SOPh bond to give amine 52. Reagents and conditions: (i) 17 (1.2 equiv.), THF, −40 °C, 20 min; (ii) E−X; [b] I2, THF, 25 °C, 20 min; [c] TsCN, 25 °C, 2 h; [d] Pd(OAc)2 (5 mol%), XantPhos (10 mol%), 40 °C, 4 h; (iii) m‐CPBA (1.5 equiv.), 0 °C to 25 °C, 2 h; (iv) pyrrolidine (1.5 equiv.), 0 °C, 20 min. [a] Isolated yield of analytically pure compounds.
Furthermore, oxidation of sulfide 50 b with m‐CPBA (1.5 equiv., 25 °C, 2 h) afforded the sulfoxide 51 as a pure compound in 85 % yield. Reacting sulfoxide 51 with pyrrolidine (1.5 equiv., 0 °C, 20 min) led to a selective substitution of the sulfoxide moiety (and not a substitution of the chloride) giving amine 52 in 46 % yield. The structure of 52 was confirmed by X‐ray analysis. [17]
In addition, magnesiation of sulfoxide 51 with TMPMgCl ⋅ LiCl (17) in THF (−60 °C, 1 min) led to a fast metalation at the 7‐position 53 (Scheme 13). The iodolysis of 53 afforded an unstable iodo‐derivative 54 a which was characterized by mass spectrometry, [17] but was too unstable to record full analytical data. Therefore, we quenched 53 with allyl bromide (2 equiv., 25 °C, 0.5 h) in the presence of CuCN⋅2LiCl (50 mol%) and in this case we were able to isolate fully substituted 54 b in 58 % yield. The structure of 54 b was confirmed by X‐ray analysis. [17]
Scheme 13.
Magnesiation of imidazopyridazines 51 using TMPMgCl ⋅ LiCl (17) followed by quenching with electrophiles giving sulfoxides of type 54. Or, by a two‐step reaction sequence: quenching with electrophiles followed by subsequent nucleophilic substitution of the C‐SOPh bond with pyrrolidine to give amines of type 55. Reagents and conditions: (i) 17 (1.2 equiv.), THF, −60 °C, 1 min; (ii) E−X, THF, 25 °C, 1 h; (iii) E−X, THF, 25 °C, 1 h; (iv) Pyrrolidine (5 equiv.), THF, 10 min. [a] Isolated yield of analytically pure compounds. [b] The allylation and acylation was mediated by CuCN ⋅ 2 LiCl (50 mol%).
We suspected that the sulfoxide moiety was responsible for the instability of these heterocycles. We overcame this problem by in situ treatment of sulfoxides with pyrrolidine [41] (5 equiv. 25 °C, 10 min) to give penta‐substituted imidazo[1,2‐b]pyridazines 55 a–55 d in 30–70 %.
Conclusion
In summary, by using theoretical calculations of new N‐heterocyclic scaffolds 1 b and 2 b, we were able to establish a reliable protocol for the functionalization of most positions of 5,6‐fused bicyclic pyrazolopyrimidines of type 1 b and imidazolopyridazines of type 2 b combining nucleophilic addition of Grignard reagents (in the case of 1 b) and successive metalations using various TMP‐zinc and magnesium bases. This study allowed a straightforward and rational functionalization of the two scaffolds of pyrazolo[1,5‐a]pyrimidines (1 a) and imidazo[1,2‐b]pyridazines (2 a). Further extensions of this approach with the help of theoretical calculations and consideration for organometallic functionalizations of other complex N‐heterocycles are currently underway.
Experimental
Full details of materials, synthetic procedures and product analysis can be found in the Supporting Information.
Deposition Number(s) 2155748 (26), 2155751 (32), 2155749 (46 c), 2155750 (52), 2155752 (54 b) contain(s) the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
Conflict of interest
The authors declare no conflict of interest.
1.
Supporting information
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supporting Information
Acknowledgements
We thank the LMU Munich and the DFG for financial support. We thank Albemarle (Hoechst, Germany) and Novartis (Basel, Switzerland) for the generous gift of chemicals and fruitful discussions with the Novartis team. Open Access funding enabled and organized by Projekt DEAL.
Dedicated to our colleague Professor Anja Hoffmann-Röder on the occasion of her 50th birthday.
S. Kumar Rout, A. Kastrati, H. Jangra, K. Schwärzer, A. S. Sunagatullina, M. Garny, F. Lima, C. E. Brocklehurst, K. Karaghiosoff, H. Zipse, P. Knochel, Chem. Eur. J. 2022, 28, e202200733.
Data Availability Statement
The data that support the findings of this study are available in the supplementary material of this article.
References
- 1.
- 1a. Taylor R. D., MacCoss M., Lawson A. D. G., J. Med. Chem. 2014, 57, 5845–5859; [DOI] [PubMed] [Google Scholar]
- 1b. Vitaku E., Smith D. T., Njardarson J. T., J. Med. Chem. 2014, 57, 10257–10274. [DOI] [PubMed] [Google Scholar]
- 2.
- 2a. Kerru N., Gummidi L., Maddila S., Gangu K. K., Jonnalagadda S. B., Molecules 2020, 25, 1909–1951; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2b. Khan E., ChemistrySelect 2021, 6, 3041–3064. [Google Scholar]
- 3. Pitt W. R., Parry D. M., Perry B. G., Groom C. R., J. Med. Chem. 2009, 52, 2952–2963. [DOI] [PubMed] [Google Scholar]
- 4.
- 4a. Cherukupalli S., Karpoormath R., Chandrasekaran B., Hampannavar G. A., Thapliyal N., Palakollu V. N., Eur. J. Med. Chem. 2017, 126, 298–352; [DOI] [PubMed] [Google Scholar]
- 4b. Al-Azmi A., Curr. Org. Chem. 2019, 23, 721–743; [Google Scholar]
- 4c. Aras-Gómez A., Godoy A., Portilla J., Molecules 2021, 26, 2708–2743.34063043 [Google Scholar]
- 5. Rao R. N., Chanda K., Bioorg. Chem. 2020, 99, 103801–103849. [DOI] [PubMed] [Google Scholar]
- 6.
- 6a. Federman N., McDermott R., Expert Rev. Clin. Pharmacol. 2019, 12, 931–939; [DOI] [PubMed] [Google Scholar]
- 6b. Scott L. J., Drugs 2019, 79, 201–206. [DOI] [PubMed] [Google Scholar]
- 7. Jusseau X., Cleator E., Maton W. M., Chen Q., Geertman R., Yuan Y., Wang X., Wei H., Medina F., Giannerini M., Org. Process Res. Dev. 2022, 26, 3, 976–986. [Google Scholar]
- 8. Guo H. Y., Liu Y., Hu N., Yu S. D., Zhou Y. C., Shi Y. G., Zhang B., Wei M., Liu J. H., Luo S. L., Tang Y. Z., Song P. H., Guo Y., Liu S. X., Su D., Zhang S., Song M. X., Zhou X., Hong Y., Chen S. S., Cheng Z. Z., Young S., Wei Q., Wang S. H., Wang W. Q., Lv L., Wang F., Xu P. H., Sun Z. H., Xing M. H., Li N., Zhang W., Wang B. Z., Liu D. G., Sun J. Z., Zhou P. D., Li W., Liu B. L., Wang L., Wang W. Z., J. Med. Chem. 2019, 62, 7923–7940. [DOI] [PubMed] [Google Scholar]
- 9. Manach C. L., Paquet T., Cabrera D. G., Younis Y., Taylor D., Wiesner L., Lawrence N., Schwager S., Waterson D., Witty M. J., Wittlin S., Street L. J., Chibale K., J. Med. Chem. 2014, 57, 8839–8848. [DOI] [PubMed] [Google Scholar]
- 10.
- 10a. Snégaroff K., Nguyen T. T., Marquise N., Halauko Y. S., Harford P. J., Roisnel T., Matulis V. E., Ivashkevich O. A., Chevallier F., Wheatley A. E. H., Gros P. C., Mongin F., Chem. Eur. J. 2011, 17, 13284–13297; [DOI] [PubMed] [Google Scholar]
- 10b. Kadiyala R. R., Tilly D., Nagaradja E., Roisnel T., Matulis V. E., Ivashkevich O. A., Halauko Y. S., Chevallier F., Gros P. C., Mongin F., Chem. Eur. J. 2013, 19, 7944–7960; [DOI] [PubMed] [Google Scholar]
- 10c. Nagaradja E., Bentabed-Ababsa G., Scalabrini M., Chevallier F., Philippot S., Fontanay S., Duval R. E., Halauko Y. S., Ivashkevich O. A., Matulis V. E., Roisnel T., Mongin F., Bioorg. Med. Chem. 2015, 23, 6355–6363; [DOI] [PubMed] [Google Scholar]
- 10d. Hedidi M., Maillard J., Erb W., Lassagne F., Halauko Y. S., Ivashkevich O. A., Matulis V. E., Roisnel T., Dorcet V., Hamzé M., Fajloun Z., Baratte B., Ruchaud S., Bach S., Bentabed-Ababsa G., Mongin F., Eur. J. Org. Chem. 2017, 5903–5915; [Google Scholar]
- 10e. Balkenhohl M., Jangra H., Makarov I. S., Yang S.-M., Zipse H., Knochel P., Angew. Chem. Int. Ed. 2020, 59, 14992–14999; [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. 2020, 132, 15102–15109. [Google Scholar]
- 11.
- 11a. El Akkaoui A., Berteina-Raboin S., Mouaddib A., Guillaumet G., Eur. J. Org. Chem. 2010, 862–871; [Google Scholar]
- 11b. Miyamoto N., Oguro Y., Takagi T., Iwata H., Miki H., Hori A., Imamura S., Bioorg. Med. Chem. 2012, 20, 7051–7058; [DOI] [PubMed] [Google Scholar]
- 11c. Maligres P. E., Li J., Krska S. W., Schreier J. D., Raheem I. T., Angew. Chem. Int. Ed. 2012, 51, 9071–9074; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2012, 124, 9205–9208; [Google Scholar]
- 11d. Yang Y., Chew X., Johannes C. W., Robins E. G., Jong H., Lim Y. H., Eur. J. Org. Chem. 2014, 7184–7192; [Google Scholar]
- 11e. Le Manach C., Paquet T., Brunschwig C., Njoroge M., Han Z., Cabrera D. G., Bashyam S., Dhinakaran R., Taylor D., Reader J., Botha M., Churchyard A., Lauterbach S., Coetzer T. L., Birkholtz L. M., Meister S., Winzeler E. A., Waterson D., Witty M. J., Wittlin S., Jiménez-Díaz M.-B., Santos Martínez M., Ferrer S., Angulo-Barturen I., Street L. J., Chibale K., J. Med. Chem. 2015, 58, 8713–8722; [DOI] [PubMed] [Google Scholar]
- 11f. Yong F. F., Mak A. M., Wu W., Sullivan M. B., Robins E. G., Johannes C. W., Jong H., Lim Y. W., ChemPlusChem 2017, 82, 750–757; [DOI] [PubMed] [Google Scholar]
- 11g. Dong X.-Y., Zhang Y.-F., Ma C.-L., Gu Q.-S., Wang F.-L., Li Z.-L., Jiang S.-P., Liu X.-Y., Nat. Chem. 2019, 11, 1158–1166. [DOI] [PubMed] [Google Scholar]
- 12. Whisler M. C., MacNeil S., Snieckus V., Beak P., Angew. Chem. Int. Ed. 2004, 43, 2206–2225; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2004, 116, 2256–2276. [Google Scholar]
- 13.
- 13a. Jaric M., Haag B. A., Unsinn A., Karaghiosoff K., Knochel P., Angew. Chem. Int. Ed. 2010, 49, 5451–5455; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2010, 122, 5582–5586; [Google Scholar]
- 13b. Duez S., Steib A. K., Manolikakes S. M., Knochel P., Angew. Chem. Int. Ed. 2011, 50, 7686–7690; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2011, 123, 7828–7832; [Google Scholar]
- 13c. Chen Q., du Jourdin X. M., Knochel P., J. Am. Chem. Soc. 2013, 135, 4958–4961; [DOI] [PubMed] [Google Scholar]
- 13d. Groll K., Manolikakes S. M., du Jourdin X. M., Jaric M., Bredihhin A., Karaghiosoff K., Carell T., Knochel P., Angew. Chem. Int. Ed. 2013, 52, 6776–6780; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 6909–6913; [Google Scholar]
- 13e. Balkenhohl M., Jangra H., Lenz T., Ebeling M., Zipse H., Karaghiosoff K., Knochel P., Angew. Chem. Int. Ed. 2019, 58, 9244–9247; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2019, 131, 9344–9348. [Google Scholar]
- 14.
- 14a. Li Z., Jangra H., Chen Q., Mayer P., Ofial A. R., Zipse H., Mayr H., J. Am. Chem. Soc. 2018, 140, 5500–5515; [DOI] [PubMed] [Google Scholar]
- 14b. Mood A., Tavakoli M., Gutman E., Kadish D., Baldi P., Van Vranken D. L., J. Org. Chem. 2020, 85, 4096–4102. [DOI] [PubMed] [Google Scholar]
- 15. Wunderlich S. H., Knochel P., Angew. Chem. Int. Ed. 2007, 46, 7685–7688; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2007, 119, 7829–7832. [Google Scholar]
- 16.
- 16a. Krasovskiy A., Krasovskaya V., Knochel P., Angew. Chem. Int. Ed. 2006, 45, 2958–2961; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2006, 118, 3024–3027; [Google Scholar]
- 16b. Krinninger C., Spec. Chem. Mag. 2010, 30, 20–21; [Google Scholar]
- 16c. Unsinn A., Rohbogner C. J., Knochel P., Adv. Synth. Catal. 2013, 355, 1553–1560; [Google Scholar]
- 16d. Schwärzer K., Tüllmann C. P., Graβl S., Górski B., Brocklehurst C. E., Knochel P., Org. Lett. 2020, 22, 1899–1902. [DOI] [PubMed] [Google Scholar]
- 17.See Supporting Information.
- 18. Knochel P., Yeh M. C. P., Berk S. C., Talbert J., J. Org. Chem. 1988, 53, 2392–2394. [Google Scholar]
- 19. Negishi E.-I., Angew. Chem. Int. Ed. 2011, 50, 6738–6764; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2011, 123, 6870–6897. [Google Scholar]
- 20.
- 20a. Farina V., Krishnan B., J. Am. Chem. Soc. 1991, 113, 9585–9595; [Google Scholar]
- 20b. Farina V., Kapadia S., Krishnan B., Wang C., Liebeskind L. S., J. Org. Chem. 1994, 59, 5905–5911; [Google Scholar]
- 20c. Klement I., Rottländer M., Tucker C. E., Majid T. N., Knochel P., Venegas P., Cahiez G., Tetrahedron 1996, 52, 7201–7220. [Google Scholar]
- 21.
- 21a.T. Verhelst, S. Verbeeck, O. Ryabtsova, S. Depraetere, B. U. W. Maes, Org. Lett. 2011, 13, 2, 272–275; [DOI] [PubMed]
- 21b.L. Kürti, B. Czakó, in Strategic applications of named reactions in organic synthesis, Elsevier Academic Press, Amsterdam, Boston, 2005, p. 80.
- 22. Kerru N., Gummidi L., Maddila S., Gangu K. K., Jonnalagadda S. B., Molecules 2020, 25, 1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.
- 23a. Andersson H., Gustafsson M., Bostroem D., Olsson R., Almqvist F., Angew. Chem. Int. Ed. 2009, 48, 3288–3291; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2009, 121, 3338–3341; [Google Scholar]
- 23b. Bull J. A., Mousseau J. J., Pelletier G., Charette A. B., Chem. Rev. 2012, 112, 2642–2713; [DOI] [PubMed] [Google Scholar]
- 23c. Bertuzzi G., Bernardi L., Fochi M., Catalysts 2018, 8, 632. [Google Scholar]
- 24. Piller F. M., Metzger A., Schade M. A., Haag B. A., Gavryushin A., Knochel P., Chem. Eur. J. 2009, 15, 7192–7202. [DOI] [PubMed] [Google Scholar]
- 25. Fujiki K., Tanifuji N., Sasaki Y., Yokoyama T., Synthesis 2002, 3, 343–348. [Google Scholar]
- 26.The stereochemistry was determined using NMR-spectroscopy in combination with the Karplus equation: Karplus M., J. Am. Chem. Soc. 1963, 85, 2870–2871. [Google Scholar]
- 27.
- 27a. Metzger A., Schade M. A., Knochel P., Org. Lett. 2008, 10, 1107–1110; [DOI] [PubMed] [Google Scholar]
- 27b. Barder T. E., Walker S. D., Martinelli J. R., Buchwald S. L., J. Am. Chem. Soc. 2005, 127, 4685–4696. [DOI] [PubMed] [Google Scholar]
- 28. Billingsley K., Buchwald S. L., J. Am. Chem. Soc. 2007, 129, 3358–3366. [DOI] [PubMed] [Google Scholar]
- 29. Phillipson L. J., Segal D. H., Nero T. L., Parker M. W., Wan S. S., de Silva M., Guthridge M. A., Wei A. H., Burns C. J., Bioorg. Med. Chem. 2015, 23, 6280–6296. [DOI] [PubMed] [Google Scholar]
- 30. Zhang Y., Liu Y., Zhou Y., Zhang Q., Han T., Tang C., Fan W., Bioorg. Med. Chem. Lett. 2021, 31, 127712. [DOI] [PubMed] [Google Scholar]
- 31. Yu W., Huang G., Zhang Y., Liu H., Dong L., Yu X., Li Y., Chang J., J. Org. Chem. 2013, 78, 10337–10343. [DOI] [PubMed] [Google Scholar]
- 32. Krämer A., Kurz C. G., Berger B.-T., Celik I. E., Tjaden A., Greco F. A., Knapp S., Hanke T., Eur. J. Med. Chem. 2020, 208, 112770. [DOI] [PubMed] [Google Scholar]
- 33.
- 33a. Krasovskiy A., Knochel P., Angew. Chem. Int. Ed. 2004, 43, 3333–3336; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2004,116, 3396–3399; [Google Scholar]
- 33b. Ziegler D. S., Wei B., Knochel P., Chem. Eur. J. 2019, 25, 2695–2703. [DOI] [PubMed] [Google Scholar]
- 34.
- 34a. Ren H., Knochel P., Chem. Commun. 2006, 726–728; [DOI] [PubMed] [Google Scholar]
- 34b. Schwärzer K., Rout S. K., Bessinger D., Lima F., Brocklehurst C. E., Karaghiosoff K., Bein T., Knochel P., Chem. Sci. 2021, 12, 12993–13000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Sonogashira K., J. Organomet. Chem. 2002, 653, 46–49. [Google Scholar]
- 36. Unsinn A., Ford M. J., Knochel P., Org. Lett. 2013, 15, 1128–1131. [DOI] [PubMed] [Google Scholar]
- 37. Tamao K., Sumitani K., Kumada M., J. Am. Chem. Soc. 1972, 94, 4374–4376. [Google Scholar]
- 38. Benischke A. D., Le Corre G., Knochel P., Chem. Eur. J. 2017, 23, 778–782. [DOI] [PubMed] [Google Scholar]
- 39. Piller F. M., Metzger A., Schade M. A., Haag B. A., Gavryushin A., Knochel P., Chem. Eur. J. 2009, 15, 7192–7202. [DOI] [PubMed] [Google Scholar]
- 40. Kranenburg M., van der Burgt Y. E. M., Kamer P. C. J., van Leeuwen P. W. N. M., Goubitz K., Fraanje J., Organometallics 1995, 14, 3081. [Google Scholar]
- 41. Miyamoto T., Egawa H., Shibamori K.-I., Matsuraoto J.-I., J. Heterocycl. Chem. 1987, 24, 1333–1339. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supporting Information
Data Availability Statement
The data that support the findings of this study are available in the supplementary material of this article.